Global Crohn's Disease Forecast and Market Analysis Report 2020-2027 - Despite Formulary Constraints, Novel Pipeline Drugs will Expand the Market
Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Crohn's Disease Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering.
As specialty products, therapies for Crohn's disease (CD) can be expensive, and formulary positioning is paramount to product uptake. Payers are settled in vital contracts that lead them to prioritize broad immunology drugs Humira and Remicade.
This has posed a high barrier to newer entrants to the market, which cannot compete in volume and rebates. Biosimilar and generic competition will further undermine the likely premium pricing of newer drugs and pipeline products.
Over the next decade, all key marketed brands for CD will have faced patent expiry. Thus far, the European market has taken the brunt of biosimilar erosion, with earlier launches and more acceptance compared to other countries. In the US, biosimilars will face challenges in usurping branded anti-TNFs, with adalimumab biosimilars not expected until 2023, substantial originator rebates, and exclusive contracting with payers.
Over time, biosimilar penetration is anticipated to gain more momentum as international real-world evidence accumulates and long-term data support biosimilar efficacy and safety. This should allow physicians and patients to grow their confidence and familiarity with biosimilars and encourage uptake.
Nevertheless, the CD market is projected to expand, propelled by a growing patient caseload and the introduction of pipeline products. The publisher estimates that in 2018, there were 6.1 million prevalent cases of CD worldwide, and forecasts that number to increase to 6.5 million prevalent cases by 2027.
The entry of novel drug classes will drive growth of the CD market, despite facing cost-related barriers to uptake. The pipeline holds distinct prospects that aim to treat non-responders, including the oral JAK inhibitors Jyseleca and Rinvoq. These will be welcomed for their distinguished mechanisms of action, and their oral formulation will further offer unprecedented convenience in the CD treatment algorithm.
Targeting global markets broadens their commercial potential as they are being investigated across the US, Japan, and Europe. Advantageously, over the forecast period, Rinvoq and Jyseleca will not encounter the increasing biosimilar competition that will directly erode sales of already marketed drugs. On the other hand, newer premium-priced entrants will likely be relegated to later lines of therapy after cheaper conventional drugs and biosimilars.
Significant unmet needs include targeting inadequate responders to biologic and conventional therapies, as well as underserved patients with fistulas. In terms of clinical trials, active comparators and the endoscopic endpoints should be prioritized as there is a stark absence of head-to-head data and the field is moving towards endoscopic treatment goals. Additionally, new mechanisms of action and convenient oral therapies that are safe and effective are desirable. Pricing will be critical to secure favorable positioning in formularies and maximize commercial opportunities.
Key Topics Covered:
OVERVIEW
Latest key takeaways
DISEASE BACKGROUND
Definition
Symptoms
Patient segmentation
TREATMENT
ACG treatment guidelines
ECCO treatment guidelines
NICE treatment guidelines
EPIDEMIOLOGY
Prevalence methodology
MARKETED DRUGS
PIPELINE DRUGS
KEY REGULATORY EVENTS
Japan Nods Include Global Firsts For Duvroq, Vafseo And First Local Biosimilar Humira
EU Approves Takeda's Injectable Entyvio for IBD
Part B Drugs At Home: Medicare Policy Responds To COVID-Driven Access Concerns
Alberta Is Second Canadian Province To Switch To Biosimilars
CHMP Positive On Pfizer's Adalimumab
Keeping Track Of Approvals: Two Novel Drugs (Givlaari And Xcopri), A Project Orbis Collaboration (Calquence) And Another Humira Biosimilar
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
Cytocom Goes Public Via Merger With Cleveland BioLabs
UCB, Ferring Will Co-Promote Cimzia Syringe For Crohn's In US
Gilead Moves Into Microbiome In Deal With Second Genome
Beximco And Mylan Strike Biosimilars Deal
Asia Deal Watch: Mundipharma Will Sell Samsung Bioepis' Biosimilars In Taiwan, Hong Kong
AZ Gets IBD Drug Back From Allergan
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events
DRUG ASSESSMENT MODEL
Biologic DMARDs
Non-biologic DMARDs
Stem cell therapy
Antibiotics
MARKET DYNAMICS
FUTURE TRENDS
Despite formulary constraints, novel pipeline drugs will expand the market
Biosimilar erosion of key brands will intensify over the next 10 years
CONSENSUS FORECASTS
RECENT EVENTS AND ANALYST OPINION
Tremfya for Crohn's Disease (October 12, 2020)
Stelara for Crohn's Disease (February 13, 2020)
PRV-6527 for Crohn's Disease (October 22, 2019)
Inflectra for Crohn's Disease (September 19, 2019)
Multiple Drugs for Crohn's Disease (June 25, 2019)
Mirikizumab for Crohn's Disease (May 21, 2019)
KEY UPCOMING EVENTS
UNMET NEEDS
There is critical unmet need for predictive biomarkers
Biologics with rapid onset and sustained remission
Novel oral treatments
Diverse head-to-head trials and trials for fistulas
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/fuuwqf
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900